Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 16/20 | 1.00 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.67 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6810717 | 0.81 | TRPV1 (0.68) | TRPV1KCNJ5KCNJ3LMNAMAPT | |
| SCHEMBL6583065 | 0.81 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL3783615 | 0.78 | KCNJ5 (0.65) | TRPV1KCNJ5KCNJ3LMNAMAPT | |
| SCHEMBL6584798 | 0.78 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL26546756 | 0.75 | KDR (0.76) | TRPV1KCNJ5KCNJ3LMNAMAPT | |
| SCHEMBL5804247 | 0.74 | KDR (0.69) | TRPV1KCNJ5KCNJ3LMNAMAPT | |
| SCHEMBL3544378 | 0.73 | LMNA (0.62) | TRPV1KCNJ5KCNJ3LMNAMAPT | |
| SCHEMBL5631971 | 0.73 | LMNA (0.70) | TRPV1LMNAMAPTMEN1KMT2A | |
| SCHEMBL5658571 | 0.73 | TRPV1 (0.77) | TRPV1 | |
| SCHEMBL4443052 | 0.72 | KDR (0.71) | TRPV1KCNJ5KCNJ3LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259875-A1 | Amine derivatives | BAYER HEALTHCARE AG (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-1414788-A1 | NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | Bayer HealthCare AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003014064-A1 | NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259875-A1 | Amine derivatives | AVPR1A, GRIN1, OPRL1 | TRPV1 14/4885KCNJ5 806/4885KCNJ3 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.